Cartesian Therapeutics Reports Q2 2026 Financial Results with $15.8M Net Income

Cartesian Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net income of $15.8 million, a slight decrease from $15.9 million in the same period last year. The company did not generate any revenue from collaboration and licensing agreements during the quarter, compared to $0.3 million in grant revenue in the prior year. For the six months ended June 30, 2026, Cartesian recorded a net loss of $23.4 million, significantly higher than the $1.8 million loss reported for the same period in 2025. The increase in losses was attributed to higher research and development expenses, which rose to $39.9 million from $29.5 million year-over-year, primarily due to costs associated with the ongoing Phase 3 AURORA trial for its lead product candidate, Descartes-08.

The company's total operating expenses for the second quarter were $29.2 million, up from $22.1 million in the previous year, reflecting a 32% increase. This rise was driven by a 37% increase in research and development expenses, which reached $20.4 million, and a 20% increase in general and administrative expenses, totaling $8.7 million. Cartesian's accumulated deficit as of June 30, 2026, stood at $845.8 million, indicating the ongoing financial challenges faced by the company as it continues to invest heavily in its clinical programs.

In terms of strategic developments, Cartesian entered into a Loan and Security Agreement with K2 HealthVentures LLC in May 2026, securing a senior secured term loan facility of up to $150 million. As of June 30, 2026, the company had drawn $50 million under this agreement. The loan is structured in four tranches, with specific milestones tied to the availability of additional funds. This financing is expected to support the company's ongoing research and development efforts, particularly for Descartes-08, which has received Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation from the FDA.

Operationally, Cartesian's cash, cash equivalents, and restricted cash totaled $149.3 million as of June 30, 2026, which the company believes will fund its operations for at least the next 12 months. The company has also been active in equity financing, raising approximately $19.3 million from the sale of common stock under its at-the-market program during the first half of 2026. Cartesian's employee headcount has increased as it continues to expand its clinical and administrative teams to support its growth and development objectives.

Looking ahead, Cartesian anticipates continued operating losses as it advances its clinical programs and seeks regulatory approvals for its product candidates. The company remains focused on securing additional funding through various means, including equity offerings and collaborations, to support its long-term strategy. The successful development and commercialization of its product candidates will be critical for achieving profitability in the future.